Kiran K Jadhav

The purpose of this research was to develop a desired topical formulation containing clotrimazole for treatment of fungal infections like eczema, itching, pruritis etc. Topical formulation enriched with SLN of clotrimazole were prepared. The solid lipid nanoparticulate dispersion of clotrimazole was prepared by hot homogenization technique using polymers like Carbopol 934, mannitol and PEG 6000. The nanoparticulate dispersion was evaluated for various parameters such as physical evaluations, particle size, diffusion studies, DSC, SEM, stability studies. The solid lipid nanoparticulate dispersion showed mean particle size less than 1000 nm. Differential scanning Calorimetry studies revealed no drug excipient incompatibility. Diffusion studies release profile of clotrimazole from nanoparticulate dispersion showed prolonged drug release. And all other evaluations were found to be complied the limits. Thus it can be concluded that formulation of SLN containing clotrimazole can be successfully formulated to localize the drug in the skin for to treat topical fungal infections.

At current 40% of the drugs were poorly soluble and were also called as “brick dust”. And the drugs which were belonging to the BCS CLASS II & IV were most eligible for this Nanosuspension technology. Here by using different methods we are reducing the particle size so the surface area will be increases ultimately it leads to increase in the bio availability. This instance was observed mostly in the case of anti-cancer drugs. Paclitaxel with 25% of Human Serum Albumin (HSA) showed very good results in terms of drug content, particle size, zeta potential and %CDR. Key words: Nanosuspension, Paclitaxel, Human Serum Albumin (HSA), High pressure homogenization.